(MENAFN- GlobeNewsWire - Nasdaq) The VKC market is expanding due to increasing allergic ocular diseases, awareness, and access to therapies. Opportunities lie in Asia Pacific and the Middle East, driven by urbanization and climate factors. Innovations in antihistamines and biologics offer growth potential, despite challenges like safety concerns and access barriers.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Vernal Keratoconjunctivitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033" report has been added to ResearchAndMarkets's offering.
The global vernal keratoconjunctivitis (VKC) market is projected to expand at a CAGR of 5.4% from 2025 to 2033, driven by rising prevalence of allergic ocular diseases, growing awareness of chronic eye conditions, and expanding access to advanced ophthalmic therapies.

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

VKC is a recurrent, seasonally aggravated allergic eye disorder that primarily affects children and young adults, particularly in warm climates. Increasing diagnosis rates, coupled with new treatment developments targeting inflammation and allergic responses, are supporting steady market growth.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Rising Prevalence and Therapeutic Advances Driving Growth
Growing incidence of allergic conjunctivitis worldwide is contributing to higher demand for VKC treatment options. Urbanization, pollution, and climate change factors have heightened allergic responses in vulnerable populations, especially in Asia Pacific and the Middle East. Pharmaceutical innovation in antihistamines, mast cell stabilizers, and corticosteroid formulations is improving treatment outcomes. The development of targeted immunomodulatory therapies and biologics is also creating new growth opportunities within the ophthalmology sector.
Safety Concerns and Access Barriers as Key Challenges
Despite market expansion, challenges include limited access to advanced treatments in developing regions and safety concerns associated with long-term corticosteroid use, such as increased risk of glaucoma and cataracts. The lack of standardized treatment guidelines across regions also hinders adoption of advanced therapies. However, the introduction of steroid-sparing drugs, increasing use of combination therapies, and rising ophthalmology-focused R&D investment are expected to mitigate these barriers over the forecast period.
Market Segmentation by Disease Type
The market is segmented into limbal vernal keratoconjunctivitis, tarsal vernal keratoconjunctivitis, and mixed vernal keratoconjunctivitis. In 2024, limbal VKC accounted for the largest market share due to its higher prevalence in tropical and subtropical regions. Tarsal VKC is also significant, particularly in developed markets where improved diagnosis is driving reported cases. Mixed VKC is less frequent but often presents with more severe symptoms, requiring combination treatment strategies.
Market Segmentation by Treatment
By treatment, the market is divided into mast cell stabilizers, antihistamines, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and other treatments. In 2024, mast cell stabilizers and antihistamines dominated due to their safety and effectiveness in long-term management. Corticosteroids remain widely prescribed for severe cases but face limitations due to side effects. NSAIDs are increasingly used for symptom relief, while the others segment, including emerging biologics and immunotherapies, is expected to grow rapidly as pipeline candidates gain approvals.
Regional Insights
In 2024, Asia Pacific led the VKC market, with high prevalence in India, Japan, and Southeast Asia, supported by expanding healthcare infrastructure. Middle East & Africa followed, where VKC is particularly common due to hot and dry climates. Europe and North America also accounted for significant shares, driven by advanced treatment adoption and greater awareness. Latin America is emerging, with rising diagnostic capacity and pharmaceutical penetration.
Competitive Landscape
The 2024 market was moderately consolidated, with both global pharmaceutical leaders and regional ophthalmic specialists active. Novartis, Alcon, and Santen Pharmaceutical led with broad ophthalmology portfolios and innovative formulations. Abbott Laboratories, AbbVie, Allergan, and Bausch Health offered antihistamines, corticosteroids, and supportive therapies. F. Hoffmann-La Roche invested in biologic therapies with potential ophthalmic applications. Laboratoires ThAa, Meda Pharmaceuticals, Senju Pharmaceutical, and Sun Pharma strengthened their positions in ophthalmic segments across Europe and Asia. Teva Pharmaceuticals expanded generics for VKC management. Competitive differentiation is shaped by treatment efficacy, safety profiles, pipeline innovation, and global distribution capabilities.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Vernal Keratoconjunctivitis market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Vernal Keratoconjunctivitis market?
• Which is the largest regional market for Vernal Keratoconjunctivitis market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Vernal Keratoconjunctivitis market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Vernal Keratoconjunctivitis market worldwide?

Companies Featured

• Abbott Laboratories
• AbbVie
• Alcon
• Allergan
• Bausch Health
• F Hoffmann La Roche
• Laboratoires Thea
• Meda Pharmaceuticals
• Novartis
• Santen Pharmaceutical
• Senju Pharmaceutical
• Sun Pharma
• Teva Pharmaceuticals

Market Segmentation

• Disease Type
• Limbal vernal keratoconjunctivitis
• Tarsal vernal keratoconjunctivitis
• Mixed vernal keratoconjunctivitis
• Treatment
• Mast cell stabilizers
• Antihistamines
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs
• Other treatments
• Route of Administration
• Oral
• Topical
• Parenteral
• Gender
• Male
• Female
• Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Region Segment (2023 - 2033; US$ Million)

• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110199359